Emicizumab - Chugai Pharmaceutical

Drug Profile

Emicizumab - Chugai Pharmaceutical

Alternative Names: ACE 910; Anti-factor IXa anti-factor X humanized bispecific antibody; CH5534262; Emicizumab-kxwh; HEMLIBRA; RG 6013; RO 5534262

Latest Information Update: 03 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antihaemorrhagics; Bispecific antibodies; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A

Most Recent Events

  • 21 Dec 2017 Phase-I clinical trials in Haemophilia A (In volunteers) in China (SC) (NCT03380780)
  • 09 Dec 2017 Pharmacodynamics data from a preclinical study in Haemophilia A presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 09 Dec 2017 Preliminary efficacy and safety data from the phase III HAVEN 4 trial in Haemophilia A presented at the 59th American Society of Hematology Annual Meeting (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top